AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17058023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 85
Study 16516777 — intervention group
Group type: EXPERIMENTAL
Intervention: Sovereign with WhiteStar
Number of subjects: 97
Study 16516777 — intervention group
Group type: COMPARATOR
Intervention: Sovereign 4.0
Number of subjects: 97
Study 14567822 — intervention group
Group type: EXPERIMENTAL
Intervention: Minihysteroscopy with a 3.5‐mm minihysteroscope
Number of subjects: 100
Study 14567822 — intervention group
Group type: COMPARATOR
Intervention: Conventional hysteroscopy with a 5‐mm endoscope
Number of subjects: 100
Study 14567822 — intervention group
Group type: EXPERIMENTAL
Intervention: Minihysteroscopy
Number of subjects: 100
Study 14567822 — intervention group
Group type: COMPARATOR
Intervention: Conventional hysteroscopy
Number of subjects: 100
Study 10588965 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human secretin (0.4 microg per kilogram of body weight)
Number of subjects: 60
Study 10588965 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study 8599309 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, alcohol appetizer
Number of subjects: 12
Study 8599309 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate appetizer
Number of subjects: 12
Study 1851063 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (3 pmol min‐1 kg‐1)
Number of subjects: 8
Study 1851063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no aldosterone infusion)
Number of subjects: 8
Study 1851063 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion (0.9% NaCl)
Number of subjects: 8
Study 6794420 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol Durules 200 mg o.m.
Number of subjects: 20
Study 6794420 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 20
Study 31801578 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs)
Number of subjects: 94
Study 31801578 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 94
Study 28302292 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg/day
Number of subjects: 250
Study 28302292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 26401704 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenserine treatment for 12 months
Number of subjects: 20
Study 26401704 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenserine treatment
Number of subjects: 20
Study 23533293 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 40
Study 23533293 — intervention group
Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 40
Study 21152932 — intervention group
Group type: COMPARATOR
Intervention: 1 × CAF (6 mg kg(‐1) body mass caffeine, 1 h before exercise)
Number of subjects: 15
Study 21152932 — intervention group
Group type: COMPARATOR
Intervention: 3 × CAF (2 mg kg(‐1) body mass caffeine on three separate occasions during the day)
Number of subjects: 15
Study 21152932 — intervention group
Group type: COMPARATOR
Intervention: PLA (0 mg caffeine)
Number of subjects: 15
Study 19245438 — intervention group
Group type: EXPERIMENTAL
Intervention: PSD502 (3 actuations of spray each containing 7.5 mg lidocaine and 2.5 mg prilocaine applied 5 min before intercourse)
Number of subjects: 300
Study 19245438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 19245438 — intervention group
Group type: EXPERIMENTAL
Intervention: PSD502
Number of subjects: 300
Study 19124906 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning and evening training (MEG)
Number of subjects: 16
Study 19124906 — intervention group
Group type: COMPARATOR
Intervention: Evening training only (EOG)
Number of subjects: 16
Study 19124906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 15158628 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 898
Study 15158628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 898
Study 15158628 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (no open-label)
Number of subjects: 898
Study 11150914 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (periCT) consisting of cyclophosphamide, epidoxorubicin, and 5-fluorouracil
Number of subjects: 197
Study 11150914 — intervention group
Group type: COMPARATOR
Intervention: No perioperative chemotherapy (control)
Number of subjects: 197
Study 9205824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine hydrobromide 0.6 mg
Number of subjects: 18
Study 9205824 — intervention group
Group type: EXPERIMENTAL
Intervention: Zamifenacin 20 mg
Number of subjects: 18
Study 9205824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8424420 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 200 mg intravenously
Number of subjects: 10
Study 8424420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3319642 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide infusion
Number of subjects: 17
Study 31464143 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone
Number of subjects: 432
Study 31464143 — intervention group
Group type: COMPARATOR
Intervention: Vaginal micronized progesterone capsules
Number of subjects: 432
Study 31000387 — intervention group
Group type: EXPERIMENTAL
Intervention: All-suture suture anchors (ASSAs)
Number of subjects: 14
Study 31000387 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture anchors (CSAs)
Number of subjects: 14
Study 28591776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonaqueous mini‐dose glucagon (MDG) (150 µg)
Number of subjects: 20
Study 28591776 — intervention group
Group type: COMPARATOR
Intervention: Glucose tablets (TABS)
Number of subjects: 20
Study 25736954 — intervention group
Group type: EXPERIMENTAL
Intervention: William's training for 8 weeks
Number of subjects: 40
Study 25736954 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 23573836 — intervention group
Group type: EXPERIMENTAL
Intervention: Single phototherapy with reflecting curtains (SPRC)
Number of subjects: 160
Study 23573836 — intervention group
Group type: COMPARATOR
Intervention: Double phototherapy (DP)
Number of subjects: 160
Study 21740240 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Silorane/Silorane adhesive (SIL)
Number of subjects: 0
Study 21740240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aelite LS/One‐Step Plus (AL)
Number of subjects: 0
Study 21740240 — intervention group
Group type: COMPARATOR
Intervention: Filtek Z250/Adper Single Bond Plus (Z)
Number of subjects: 0
Study 18261963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic plate (slotted-holes)
Number of subjects: 66
Study 18261963 — intervention group
Group type: COMPARATOR
Intervention: Static plate (fixed-holes)
Number of subjects: 66
Study 18261963 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dynamic and static plates
Number of subjects: 66
Study 18261963 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical success
Number of subjects: 66
Study 16965206 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-step treatment algorithm (washout period, anti-depressant monotherapy, lithium addition, treatment with a nonselective monoamine oxidase inhibitor, electroconvulsive therapy)
Number of subjects: 203
Study 16965206 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-step treatment algorithm
Number of subjects: 203
Study 16965206 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant monotherapy
Number of subjects: 203
Study 15577441 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfraction interval (IFI) of 4.5-5.0 hours
Number of subjects: 536
Study 15577441 — intervention group
Group type: COMPARATOR
Intervention: Interfraction interval (IFI) of 5.5-6.0 hours
Number of subjects: 536
Study 12411356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionisation sensor with a zinc battery; ionisation sensor with a zinc battery and pause button; ionisation sensor with a lithium battery and pause button; optical sensor with a lithium battery; or optical sensor with a zinc battery
Number of subjects: 2145
Study 12411356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionisation sensor with a lithium battery
Number of subjects: 2145
Study 12411356 — intervention group
Group type: EXPERIMENTAL
Intervention: Households occupied by smokers
Number of subjects: 2145
Study 12411356 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a smoker in the household
Number of subjects: 2145
Study 9798804 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC 400 mg b.d. plus clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 1 week (RbcCT)
Number of subjects: 295
Study 9798804 — intervention group
Group type: COMPARATOR
Intervention: RBC 400 mg b.d. plus clarithromycin 500 mg b.d. for 2 weeks (RbcC)
Number of subjects: 295
Study 7644253 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral mediation model
Number of subjects: 100
Study 2665352 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRC vaccine
Number of subjects: 0
Study 2665352 — intervention group
Group type: COMPARATOR
Intervention: BCG (control)
Number of subjects: 0
Study 360232 — intervention group
Group type: EXPERIMENTAL
Intervention: piracetam (Nootropil) 2400 mg/day
Number of subjects: 56
Study 360232 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study 30630559 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine-remifentanil intravenous anaesthesia
Number of subjects: 80
Study 30630559 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-remifentanil intravenous anaesthesia
Number of subjects: 80
Study 30630559 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 28667118 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 8
Study 28667118 — intervention group
Group type: COMPARATOR
Intervention: GIP(3-30)NH2
Number of subjects: 8
Study 28667118 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP + GIP(3-30)NH2
Number of subjects: 8
Study 26116874 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 806
Study 23692891 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote magnetic control (RMC)
Number of subjects: 30
Study 23692891 — intervention group
Group type: COMPARATOR
Intervention: Manual catheter control (MCC)
Number of subjects: 30
Study 21314280 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 50
Study 21314280 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral fusion (PLF)
Number of subjects: 50
Study 19803563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance intervention
Number of subjects: 306
Study 19803563 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational brochure control
Number of subjects: 306
Study 17356528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/day)
Number of subjects: 224
Study 17356528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification counseling alone
Number of subjects: 224
Study 17356528 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus lifestyle modification counseling
Number of subjects: 224
Study 17356528 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine alone
Number of subjects: 224
Study 15269618 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented infant formula (FF) with Bifidobacterium breve C50 and Streptococcus thermophilus 065
Number of subjects: 971
Study 15269618 — intervention group
Group type: COMPARATOR
Intervention: Standard infant formula (SF)
Number of subjects: 971
Study 10997483 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 39
Study 10997483 — intervention group
Group type: EXPERIMENTAL
Intervention: estrogen/glucocorticoid combination
Number of subjects: 39
Study 10997483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 39
Study 8752077 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual length of stay (longer duration)
Number of subjects: 444
Study 8752077 — intervention group
Group type: COMPARATOR
Intervention: Planned duration (3 or 6 months)
Number of subjects: 444
Study 1580345 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term group treatment program for abusive husbands
Number of subjects: 0
Study 1580345 — intervention group
Group type: COMPARATOR
Intervention: Control group of untreated abusive husbands
Number of subjects: 0
Study 3882059 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy feeds (3.6 MJ/L, 87 kcal/100 ml)
Number of subjects: 17
Study 3882059 — intervention group
Group type: COMPARATOR
Intervention: Standard energy feeds (2.7 MJ/L, 65 kcal/100 ml)
Number of subjects: 17
Study 31177994 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help diet and activity intervention with telephone-based dietitian support
Number of subjects: 62
Study 31177994 — intervention group
Group type: COMPARATOR
Intervention: Wait-list mini-intervention group
Number of subjects: 62
Study 28210843 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 795
Study 28210843 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 795
Study 28210843 — intervention group
Group type: EXPERIMENTAL
Intervention: GS (Gemcitabine plus S-1)
Number of subjects: 795
Study 26918239 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL) plus timolol gel 0.05%
Number of subjects: 30
Study 26918239 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 30
Study 23581532 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 1856
Study 23581532 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 1856
Study 23581532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1856
Study 21739686 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 60
Study 19370466 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 3% gel followed by ALA-PDT
Number of subjects: 10
Study 19370466 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel followed by ALA-PDT
Number of subjects: 10
Study 16911579 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral isthmus line (ML) recovery
Number of subjects: 48
Study 16911579 — intervention group
Group type: EXPERIMENTAL
Intervention: Roof-line (RL) recovery
Number of subjects: 48
Study 16911579 — intervention group
Group type: EXPERIMENTAL
Intervention: Reablation of lines
Number of subjects: 48
Study 16911579 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduction delay
Number of subjects: 48
Study 15224297 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy radiation dose
Number of subjects: 180
Study 15224297 — intervention group
Group type: COMPARATOR
Intervention: 15 Gy radiation dose
Number of subjects: 180
Study 15224297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 11203643 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium framework
Number of subjects: 42
Study 11203643 — intervention group
Group type: COMPARATOR
Intervention: Conventional cast framework
Number of subjects: 42
Study 11203643 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium framework prosthesis (group B)
Number of subjects: 42
Study 9315594 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 17 beta
Number of subjects: 0
Study 9315594 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 8482557 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of cyclophosphamide, Adriamycin, and cisplatin (CAP)
Number of subjects: 202
Study 8482557 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 cycles of cyclophosphamide, Adriamycin, and cisplatin (CAP)
Number of subjects: 202
Study 8482557 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of CAP (after second-look laparotomy)
Number of subjects: 202
Study 3915461 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 1.2 mg/kg
Number of subjects: 38
Study 3915461 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.3 mg/kg
Number of subjects: 38
Study 3915461 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 0.6 mg/kg
Number of subjects: 38
Study 3915461 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 10 mg/kg
Number of subjects: 38
Study 3239727 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (5 micrograms/kg)
Number of subjects: 51
Study 3239727 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg)
Number of subjects: 51
Study 3239727 — intervention group
Group type: COMPARATOR
Intervention: No anticholinergic premedication
Number of subjects: 51
Study 31850931 — intervention group
Group type: EXPERIMENTAL
Intervention: GED‐0301 (160 mg for 12 weeks followed by 40 mg continuously)
Number of subjects: 701
Study 31850931 — intervention group
Group type: EXPERIMENTAL
Intervention: GED‐0301 (alternating placebo with 40 or 160 mg every 4 weeks through week 52)
Number of subjects: 701
Study 31850931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 31850931 — intervention group
Group type: EXPERIMENTAL
Intervention: GED‐0301
Number of subjects: 701
Study 29605891 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment focused on non‐medical risk factors, lifestyle factors, and medical risk factors, with subsequent institution of risk‐specific care pathways and multidisciplinary consultation.
Number of subjects: 4302
Study 29605891 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk assessment and care pathways intervention
Number of subjects: 4302
Study 28882161 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) under general anesthesia
Number of subjects: 110
Study 28882161 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) under local anesthesia
Number of subjects: 110
Study 26333545 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RDN)
Number of subjects: 18
Study 26333545 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 18
Study 23710902 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0
Study 23710902 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study 21539581 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency laparotomy for acute intestinal disease
Number of subjects: 70
Study 18814099 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostanoids, nonselective and selective endothelin-receptor antagonists, phosphodiesterase-V inhibitors
Number of subjects: 0
Study 16870914 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (5 ppm) for 21 days or until extubation
Number of subjects: 793
Study 16870914 — intervention group
Group type: COMPARATOR
Intervention: Placebo gas
Number of subjects: 793
Study 14645934 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 191
Study 14645934 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice (BA)
Number of subjects: 191
Study 10893362 — intervention group
Group type: EXPERIMENTAL
Intervention: Seratrodast, 40 mg/d
Number of subjects: 45
Study 10893362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8831532 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc 99m HMPAO-labeled leukocyte scintigraphy
Number of subjects: 27
Study 8831532 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy
Number of subjects: 27
Study 1419642 — intervention group
Group type: EXPERIMENTAL
Intervention: Competing risk method
Number of subjects: 2850
Study 1419642 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 2850
Study 3837566 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified holding therapy (MHT)
Number of subjects: 14
Study 3837566 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 14
Study 30772283 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracentesis guided by symptoms plus manometry
Number of subjects: 124
Study 30772283 — intervention group
Group type: COMPARATOR
Intervention: Thoracentesis guided by symptoms only (control)
Number of subjects: 124
Study 30772283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 29317347 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) program presenting natural scenes for 5 minutes
Number of subjects: 20
Study 27759847 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar filgrastim (Fiprima)
Number of subjects: 0
Study 27759847 — intervention group
Group type: COMPARATOR
Intervention: Originator filgrastim
Number of subjects: 0
Study 24253831 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 2019
Study 24253831 — intervention group
Group type: COMPARATOR
Intervention: FF 100 μg
Number of subjects: 2019
Study 22152659 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstainers and light drinkers
Number of subjects: 437
Study 22152659 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinkers
Number of subjects: 437
Study 22152659 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 437
Study 22152659 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum alcohol consumption in college
Number of subjects: 437
Study 22152659 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior drinking experience
Number of subjects: 437
Study 20479702 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive TLIF using the tubular retractor system
Number of subjects: 62
Study 20479702 — intervention group
Group type: COMPARATOR
Intervention: Traditional open procedure
Number of subjects: 62
Study 19080431 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich beverage group (n = 24)
Number of subjects: 51
Study 19080431 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 27)
Number of subjects: 51
Study 15937606 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Birth (VB)
Number of subjects: 999
Study 15937606 — intervention group
Group type: COMPARATOR
Intervention: Caesarean Section (CS)
Number of subjects: 999